209 related articles for article (PubMed ID: 9232254)
1. Amphotericin B lipid complex (ABLC) for the treatment of confirmed or presumed fungal infections in immunocompromised patients with hematologic malignancies.
Mehta J; Kelsey S; Chu P; Powles R; Hazel D; Riley U; Evans C; Newland A; Treleaven J; Singhal S
Bone Marrow Transplant; 1997 Jul; 20(1):39-43. PubMed ID: 9232254
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses.
Wingard JR
Bone Marrow Transplant; 1997 Feb; 19(4):343-7. PubMed ID: 9051244
[TBL] [Abstract][Full Text] [Related]
3. Retrospective study of the renal effects of amphotericin B lipid complex when used at higher-than-recommended dosages and longer durations compared with lower dosages and shorter durations in patients with systemic fungal infections.
Hooshmand-Rad R; Reed MD; Chu A; Gotz V; Morris JA; Weinberg J; Dominguez EA
Clin Ther; 2004 Oct; 26(10):1652-62. PubMed ID: 15598482
[TBL] [Abstract][Full Text] [Related]
4. Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies--a randomized, controlled trial.
Subirà M; Martino R; Gómez L; Martí JM; Estany C; Sierra J
Eur J Haematol; 2004 May; 72(5):342-7. PubMed ID: 15059069
[TBL] [Abstract][Full Text] [Related]
5. Assessment of nephrotoxicity in patients receiving amphotericin B lipid complex: a pharmacosurveillance study in Spain.
Aguado JM; Lumbreras C; González-Vidal D;
Clin Microbiol Infect; 2004 Sep; 10(9):785-90. PubMed ID: 15355408
[TBL] [Abstract][Full Text] [Related]
6. Delayed ABLC prophylaxis after allogeneic stem-cell transplantation.
Jansen J; Akard LP; Wack MF; Thompson JM; Dugan MJ; Leslie JK; Mattison R
Mycoses; 2006 Sep; 49(5):397-404. PubMed ID: 16922792
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of amphotericin B lipid complex (ABLC) treatment in allogeneic hematopoietic cell transplant (HCT) recipients with invasive aspergillosis (IA).
Ito JI; Chandrasekar PH; Hooshmand-Rad R
Bone Marrow Transplant; 2005 Nov; 36(10):873-7. PubMed ID: 16113663
[TBL] [Abstract][Full Text] [Related]
8. Risk of reactivation of a recent invasive fungal infection in patients with hematological malignancies undergoing further intensive chemo-radiotherapy. A single-center experience and review of the literature.
Martino R; Lopez R; Sureda A; Brunet S; Domingo-Albós A
Haematologica; 1997; 82(3):297-304. PubMed ID: 9234575
[TBL] [Abstract][Full Text] [Related]
9. Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: a retrospective, nonrandomized autopsy study.
Chamilos G; Luna M; Lewis RE; Chemaly R; Raad II; Kontoyiannis DP
Clin Ther; 2007 Sep; 29(9):1980-6. PubMed ID: 18035197
[TBL] [Abstract][Full Text] [Related]
10. Treatment of invasive fungal infections with amphotericin B colloidal dispersion in bone marrow transplant recipients.
Noskin G; Pietrelli L; Gurwith M; Bowden R
Bone Marrow Transplant; 1999 Apr; 23(7):697-703. PubMed ID: 10218847
[TBL] [Abstract][Full Text] [Related]
11. Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy.
Hachem RY; Boktour MR; Hanna HA; Husni RN; Torres HA; Afif C; Kontoyiannis DP; Raad II
Cancer; 2008 Mar; 112(6):1282-7. PubMed ID: 18224662
[TBL] [Abstract][Full Text] [Related]
12. Non-comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation.
Alexander BD; Dodds Ashley ES; Addison RM; Alspaugh JA; Chao NJ; Perfect JR
Transpl Infect Dis; 2006 Mar; 8(1):13-20. PubMed ID: 16623816
[TBL] [Abstract][Full Text] [Related]
13. Amphotericin B lipid complex in the management of invasive aspergillosis in immunocompromised patients.
Chandrasekar PH; Ito JI
Clin Infect Dis; 2005 May; 40 Suppl 6():S392-400. PubMed ID: 15809925
[TBL] [Abstract][Full Text] [Related]
14. Study of renal safety in amphotericin B lipid complex-treated patients.
Alexander BD; Wingard JR
Clin Infect Dis; 2005 May; 40 Suppl 6():S414-21. PubMed ID: 15809928
[TBL] [Abstract][Full Text] [Related]
15. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS.
Sharkey PK; Graybill JR; Johnson ES; Hausrath SG; Pollard RB; Kolokathis A; Mildvan D; Fan-Havard P; Eng RH; Patterson TF; Pottage JC; Simberkoff MS; Wolf J; Meyer RD; Gupta R; Lee LW; Gordon DS
Clin Infect Dis; 1996 Feb; 22(2):315-21. PubMed ID: 8838189
[TBL] [Abstract][Full Text] [Related]
16. Amphotericin B lipid complex in pediatric patients with invasive fungal infections.
Walsh TJ; Seibel NL; Arndt C; Harris RE; Dinubile MJ; Reboli A; Hiemenz J; Chanock SJ
Pediatr Infect Dis J; 1999 Aug; 18(8):702-8. PubMed ID: 10462340
[TBL] [Abstract][Full Text] [Related]
17. Amphotericin B lipid complex in the management of antimony unresponsive Indian visceral leishmaniasis.
Sundar S; Goyal AK; Mandal AK; Makharia MK; Singh VP; Murray HW
J Assoc Physicians India; 1999 Feb; 47(2):186-8. PubMed ID: 10999086
[TBL] [Abstract][Full Text] [Related]
18. Successful use of amphotericin B lipid complex in the treatment of cryptococcosis.
Baddour LM; Perfect JR; Ostrosky-Zeichner L
Clin Infect Dis; 2005 May; 40 Suppl 6():S409-13. PubMed ID: 15809927
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of amphotericin B lipid complex in 548 children and adolescents with invasive fungal infections.
Wiley JM; Seibel NL; Walsh TJ
Pediatr Infect Dis J; 2005 Feb; 24(2):167-74. PubMed ID: 15702047
[TBL] [Abstract][Full Text] [Related]
20. Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex.
Perfect JR
Clin Infect Dis; 2005 May; 40 Suppl 6():S401-8. PubMed ID: 15809926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]